Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
Key takeaways
- Positive earnings and trial results from Estee Lauder, Moderna, and Merck are driving a sharp rally in key large‑cap stocks, boosting confidence in consumer‑discretionary and biotech sectors.
- Estee Lauder Q4 adjusted earnings: $0.39 per share (vs $0.32 estimate)
- Estee Lauder Q4 sales: $3.63 billion (vs $3.54 billion estimate)
- Estee Lauder FY27 sales guidance above estimates
What happened
U.S. stocks were mixed, but several large names surged on Wednesday. Estee Lauder jumped 17.7% to $99.15 after reporting fourth‑quarter earnings of $0.39 per share, beating the $0.32 estimate, and lifting FY27 sales guidance above consensus. Moderna (MRNA) and Merck (MRK) both rallied after announcing that the Phase 3 INTerpath‑001 trial met its primary and a key secondary endpoint, sending MRNA up 99.6% to $125.70 and MRK up 11.3% to $150.43. Other biotech and tech stocks such as Maravai,…
Why it matters
The earnings beat and guidance lift from Estee Lauder suggest stronger consumer demand and a resilient beauty market, potentially supporting the broader consumer‑discretionary sector. The INTerpath‑001 trial success for Moderna and Merck signals progress in COVID‑19 vaccine development, which could boost investor…
Short-term and longer-term
Short-term. Short‑term traders should watch EL, MRNA, and MRK for potential breakout trades, as their recent earnings beats and trial milestones have already pushed prices higher.
Longer-term. Over the next few months, investors may reassess the long‑term upside of Estee Lauder, Moderna, and Merck.